- Conditions
- Bacterial Vaginosis, Vulvovaginal Candidiasis
- Interventions
- TOL-463
- Drug
- Lead sponsor
- Toltec Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–33
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Candidiasis, Vulvovaginal
- Interventions
- VT-1161, Fluconazole
- Drug
- Lead sponsor
- Viamet
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 8
- States / cities
- Lake Worth, Florida • North Miami, Florida • Brooklyn, New York + 5 more
- Conditions
- Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
- Interventions
- vaginal cooling device
- Device
- Lead sponsor
- Coologics, Inc
- Industry
- Eligibility
- 22 Years to 49 Years · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 10
- States / cities
- Jacksonville, Florida • Miami, Florida • Smyrna, Georgia + 7 more
- Conditions
- Vaginitis
- Interventions
- Terazol or oral fluconazole for candidal vaginitis, Metronidazole or Clindamycin for Bacterial Vaginosis, Flagyl for definitively diagnosed vaginal trichomoniasis, Empiric Management
- Drug · Other
- Lead sponsor
- Agency for Healthcare Research and Quality (AHRQ)
- Federal
- Eligibility
- 18 Years to 52 Years · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
- Interventions
- Oral Encochleated Amphotericin B (CAMB)
- Drug
- Lead sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Vulvovaginal Candidiasis
- Interventions
- MGCD290
- Drug
- Lead sponsor
- MethylGene Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • San Diego, California • Lake Worth, Florida + 16 more
- Conditions
- Microbiome, Antibiotic-Induced VVC, Vaginal Candidiasis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Oteseconazole (VT-1161), Placebo
- Drug
- Lead sponsor
- Mycovia Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
- Conditions
- Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal, Vaginitis, Monilial
- Interventions
- CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%), CD101 External ointment (1%), Fluconazole
- Drug
- Lead sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more